European Commission approves MSD's MAA for SYCREST in manic episodes associated with bipolar I disorder

MSD announced today that the European Commission has approved the Marketing Authorization Application (MAA) for SYCREST® (asenapine) sublingual tablets for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. Today's decision was based on recommendations from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). The ...

Rough youth fuels advocate's fire

Stan Appelbaum has led volunteer groups for two decades and is a watchdog on children's and mental health issues. |

Researchers to test Merck cancer drug on HIV

EPA/Justin LaneA view of a sign for Merck & Co. at the company's complex in Rahway, New Jersey, March 9, 2009. The 30-year-long search for a cure for AIDS, the world’s deadliest viral infection, may get a renewed boost from...

Help & support

n upcoming health education events at martin's point health care: at 161 Corporate Drive, Pease International Tradeport, Portsmouth. (800) 260-6681.

AIDS Cure Quest to Kill `Sleeping' Viruses Enlists Merck Cancer Medicine

The 30-year-long search for a cure for AIDS, the world’s deadliest viral infection, may get a renewed boost from an unlikely source: a little-used Merck & Co. cancer drug.